Stocks TelegraphStocks Telegraph
Stock Ideas

MREO Financial Statements and Analysis

NASDAQ : MREO

Mereo BioPharma Group

$0.24
0.0021+0.87%
At Close 4:00 PM
50
BESG ScoreESG Rating

FINANCIAL STATEMENTS

An instrumental part of fundamental analysis is measuring key indicators of an asset, which are the factors that can influence its value and price. However, sometimes investors show more interest in financial statements with other factors to determine whether investing in that company is the right decision. Financial statements of a company include:

  • Balance Sheet
  • Income Statement
  • Cash Flow Statement

Income Statement

A company's income statement helps investors and business owners determine whether the company is profitable or losing money. Profitability is a key factor investors consider before investing in a stock. Income statements provide them with information about a company's profitability over time. The statement also enables them to observe trends in company spending and earnings since it breaks down individual costs and revenues. Income statements also provide details on where a company's money is going when it isn't profitable or its profits fluctuate.

DateJun 30, 2026Mar 31, 2026Sep 30, 2025Jun 30, 2025Mar 31, 2025
reported currencyUSDUSDUSDUSDUSD
calendar year20262026202520252025
periodQ2Q1Q3Q2Q1
revenue000500.00K0
cost of revenue0304.488K1.00K132.00K0
gross profit0-304.488K-1.00K368.00K0
gross profit ratio0000.7360
research and development expenses1.808M4.739M3.824M5.373M3.93M
general and administrative expenses5.222M4.019M6.045M5.494M7.272M
selling and marketing expenses00000
selling general and administrative expenses5.222M4.019M6.045M5.494M7.272M
other expenses0-311.224K145.00K00
operating expenses7.03M8.447M10.014M10.867M11.202M
cost and expenses7.03M8.751M10.015M10.999M11.202M
interest income278.00K326.451K500.973K589.00K659.00K
interest expense16.00K20.00K27.831K24.00K180.00K
depreciation and amortization0304.488K54.00K298.00K270.00K
ebitda-6.989M-8.447M-9.815M-14.294M-12.437M
ebitda ratio000-28.5880
operating income-7.03M-8.751M-10.015M-10.499M-11.202M
operating income ratio000-20.9980
total other income expenses net25.00K1.949M2.991M-4.117M-1.685M
income before tax-7.005M-6.803M-7.024M-14.616M-12.887M
income before tax ratio000-29.2320
income tax expense0-94.84K000
net income-7.005M-6.708M-7.024M-14.616M-12.887M
net income ratio000-29.2320
eps-0.05-0.042-0.05-0.093-0.082
eps diluted-0.05-0.042-0.05-0.093-0.082
weighted average shs out160.713M160.361M159.989M159.887M156.856M
weighted average shs out dil160.713M160.361M159.989M159.887M156.856M
Graph

Balance Sheet

Balance sheet summarizes a company's financials and can be used as a basis by investors to determine the value of a company. It shows the value of the stock, as well as the assets and liabilities of the company. A company's balance sheet displays how its assets are put to use and how those assets are financed, based on the liabilities section. Both investors and analysts analyze a company's balance sheet to determine how it allocates its resources.

DateJun 30, 2026Mar 31, 2026Sep 30, 2025Jun 30, 2025Mar 31, 2025
reported currencyUSDUSDUSDUSDUSD
calendar year20262026202520252025
periodQ2Q1Q3Q2Q1
cash and cash equivalents30.118M36.223M48.698M56.125M62.483M
short term investments00000
cash and short term investments30.118M36.223M48.698M56.125M62.483M
net receivables1.924M1.879M03.747M2.398M
inventory00000
other current assets1.359M1.932M3.709M1.549M2.018M
total current assets33.401M40.034M52.407M61.421M66.899M
property plant equipment net1.057M199.00K552.00K740.00K869.00K
goodwill00000
intangible assets256.00K381.00K643.00K470.00K554.00K
goodwill and intangible assets256.00K381.00K643.00K470.00K554.00K
long term investments00000
tax assets00000
other non current assets00000
total non current assets1.313M580.00K1.195M1.21M1.423M
other assets00000
total assets34.714M40.614M53.602M62.631M68.322M
account payables1.121M3.226M879.00K1.138M2.924M
short term debt1.03M0397.00K601.00K747.00K
tax payables000485.00K370.00K
deferred revenue00000
other current liabilities3.526M2.951M4.74M5.333M3.456M
total current liabilities5.677M6.177M6.016M7.557M7.497M
long term debt00000
deferred revenue non current00000
deferred tax liabilities non current00000
other non current liabilities385.00K383.00K988.00K897.00K744.00K
total non current liabilities385.00K383.00K988.00K897.00K744.00K
other liabilities00000
capital lease obligations1.03M0397.00K601.00K747.00K
total liabilities6.062M6.56M7.004M8.454M8.241M
preferred stock00000
common stock3.145M3.145M3.134M3.132M3.132M
retained earnings-514.543M-507.538M-493.667M-486.643M-472.027M
accumulated other comprehensive income loss-12.285M-12.571M-10.91M-8.643M-15.29M
other total stockholders equity552.335M551.018M548.041M546.331M544.266M
total stockholders equity28.652M34.054M46.598M54.177M60.081M
total equity28.652M34.054M46.598M54.177M60.081M
total liabilities and stockholders equity34.714M40.614M53.602M62.631M68.322M
minority interest00000
total investments00000
total debt1.03M0397.00K601.00K747.00K
net debt-29.088M-36.223M-48.301M-55.524M-61.736M
Graph

Cash Flow

A cash flow statement is regarded as a valuable indicator of profitability and the long-term outlook for a company. It assists the company in evaluating whether it has sufficient funds to cover its expenses. Essentially, a cash flow statement represents an organization's financial health. The cash flow statement, which measures the business's ability to operate in the short as well as long term, is broken down into operating, investing, and financing activities.

DateJun 30, 2026Mar 31, 2026Sep 30, 2025Jun 30, 2025Mar 31, 2025
reported currencyUSDUSDUSDUSDUSD
calendar year20262026202520252025
periodQ2Q1Q3Q2Q1
deferred income tax00000
stock based compensation1.317M1.605M02.065M2.278M
change in working capital-997.00K2.157M636.00K-843.00K-514.00K
accounts receivables0-94.84K0-744.00K952.00K
inventory00000
accounts payables-2.137M1.957M0-1.951M362.00K
other working capital1.14M298.499K636.00K1.852M-1.828M
other non cash items343.00K-1.526M-910.00K5.445M2.524M
net cash provided by operating activities-6.043M-4.312M-7.309M-7.651M-8.329M
investments in property plant and equipment0-299.497K00-20.00K
acquisitions net00000
purchases of investments00000
sales maturities of investments00000
other investing activites0-503.00300.00K0-300.00K
net cash used for investing activites0-300.00K300.00K0-320.00K
debt repayment00000
common stock issued00000
common stock repurchased00000
dividends paid00000
other financing activites62.00K00-134.00K422.00K
net cash used provided by financing activities62.00K00-134.00K422.00K
effect of forex changes on cash-62.00K-164.73K-418.00K1.427M908.00K
net change in cash-6.043M-4.769M-7.427M-6.358M-7.319M
cash at end of period30.118M36.223M48.698M56.125M62.483M
cash at beginning of period36.223M40.992M56.125M62.483M69.802M
operating cashflow-6.043M-4.312M-7.309M-7.651M-8.329M
capital expenditure0000-320.00K
free cash flow-6.043M-4.312M-7.309M-7.651M-8.649M
Graph

Frequently Asked Questions

How did Mereo BioPharma Group plc do last quarter? What was its Total Revenue and Cost of Revenue?
A company's Total Revenue reveals how much money it generates before any expenses or deductions are made. As a result, this metric informs investors/stakeholders how much money the business makes. Tracking and understanding it is essential for evaluating a company's growth. As opposed to revenue, Cost of Revenue is any expenses a business incur to generate revenue. There can be high revenue in a business, but if the costs are high, it won't make a profit and will go out of business when money runs out. Therefore, MREO generated $0.00 in revenue last quarter, while its costs came in at $0.00.
Last quarter, how much Gross Profit did Mereo BioPharma Group plc report?
A business's Gross Profit is a key indicator of its profitability and financial performance. In other words, it reflects how efficiently a business uses labor, raw materials, and other resources. Mereo BioPharma Group plc reported a $0.00 Gross Profit for the quarter ended Jun 30, 2026.
Have MREO's Total Operating Expenses and Operating Income been favorable recently?
Operational Expenses represent the costs a company must incur to generate revenue, which is the ultimate goal of a business, whereas Operating Income shows the revenue left after operational direct and indirect costs have been deducted. MREO incurred $7.03M worth of Operating Expenses, while it generated -$7.03M worth of Operating Income.
How much Net Income has MREO posted recently?
The Net Income of a company is one of the factors investors consider when investing in the company. According to recent earnings report from Mereo BioPharma Group plc, the company generated -$7.01M in Net Income. When a company has a history of consistent net income, investors are more likely to invest in it since they know they will get a return.
At the end of the last quarter, how much Cash and Equivalents did Mereo BioPharma Group plc have?
The amount of Cash and Cash Equivalents is an effective indicator of the financial strength and well-being of a company. An excess cash situation occurs when a company has more cash and cash equivalents than it needs for operating activities. The amount of Cash and Cash Equivalents available to Mereo BioPharma Group plc as of the end of the last quarter was $30.12M.
What are MREO's Total Net Receivables for the last quarter?
Total Net Receivables are a company's outstanding debts to its customers. Therefore, it refers to the amount that a company expects to collect from its customers. The higher a company's net receivables are, the more confident it is that it can collect money from its debtors. As of the end of the last quarter, MREO had Total Net Receivables of $1.92M.
In terms of Total Assets and Current Assets, where did Mereo BioPharma Group plc stand at?
An asset with an economic value within a year is considered a current asset. Total assets, however, also include long-term fixed assets, intangible assets, and other non-current assets. The current Assets of MREO were $33.40M, while the Total Assets stand at $34.71M.
As of the last quarter, how much Total Debt did Mereo BioPharma Group plc have?
The total debt of a business refers to how much it borrows. A company's current and long-term liabilities are added together to calculate its Total Debt. A debt ratio may be taken into account on a balance sheet by financial lenders, investors, and business leaders when making informed decisions about future loans or investments. The total amount of MREO's debt was $1.03M at the end of the last quarter.
What were MREO's Total Liabilities during the last reported quarter?
A company's total liabilities are the sum of all debts it is liable for, including any off-balance shee liabilities it may incur. This can be calculated by adding up all short-term and long-term liabilities. In its last quarter, MREO reported total liabilities of $6.06M.
How much did MREO's Working Capital change over the last quarter?
Working Capital Change for MREO was -$997.00K over the last quarter. Working Capital Change refers to the difference between net working capital amounts at the end of one accounting period and the end of another. It tells investors/stakeholders how much the company's cash flow will differ from its Net Income (i.e., after-tax profits). More powerful companies often have positive Change in Working Capital numbers as they have increased control over collecting cash from customers and delaying payments to suppliers.
MREO generated how much cash from operating activities?
An operating cash flow statement usually contains cash from operating activities in the first section. An organization's cash from operating activities refers to the money it takes in and takes out as a result of its regular business operations. MREO generated -$6.04M of Cash from Operating Activities during its recently reported quarter.
What was MREO's latest reported Net Change in Cash?
An increase or decrease in cash and cash equivalent balances within a specified period is considered the net change in cash in a cash flow statement. Furthermore, it takes into account cash changes as a result of investments, financing, and operating activities. MREO reported a -$6.04M Net Change in Cash in the most recent quarter.
logo

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep

stockstelegraph

Don't have an account?

stockstelegraph

Don't have an account?

stockstelegraph

Already have an account?

stockstelegraph
Smart Screening Tools for Exceptional Returns
stockstelegraph

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!
stockstelegraph